Strategies for Addressing Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations From the Expert Consensus Guidelines-Reference-Cited by-同舟云学术

Strategies for Addressing Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations From the Expert Consensus Guidelines

Published:2010-09 Issue:5 Volume:16 Page:306-324
ISSN:1538-1145
Container-title:Journal of Psychiatric Practice
language:en
Short-container-title:

Author:

Velligan Dawn I.,Weiden Peter J.,Sajatovic Martha,Scott Jan,Carpenter Daniel,Ross Ruth,Docherty John P.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference58 articles.

1. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications;Velligan;Psychiatr Serv,2003

2. Assessment of adherence problems in patients with serious and persistent mental illness: Recommendations from the Expert Consensus Guidelines;Velligan;J Psychiatr Pract,2010

3. Medication adherence: A review of the literature and implications for clinical practice;Julius;J Psychiatr Pract,2009

4. Cognitive and behavioural approaches to medication adherence;Scott;Advances in Psychiatric Treatment,1999

5. A pilot study of concordance therapy in individuals with bipolar disorders who are non-adherent with lithium prophylaxis;Scott;Bipolar Disord,2002

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measuring Cognitive Impairments Associated With Schizophrenia in Clinical Practice: Overview of Current Challenges and Future Opportunities;Schizophrenia Bulletin;2024-08-01

2. Family psychoeducation in schizophrenia and schizophrenia related disorder, treatment compliance, and suicidal risk reduction: questions about their relationship from a naturalistic observation;Frontiers in Psychiatry;2024-04-04

3. Long-Acting Injectable Antipsychotics—A Review on Formulation and In Vitro Dissolution;Pharmaceutics;2023-12-24

4. Why does non-adherence to treatment remain a leading cause of relapse in patients with bipolar disorder?;European Neuropsychopharmacology;2023-08

5. Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States;Journal of Medical Economics;2023-04-06